Nutriband Inc. NTRB Archives - Page 3 of 3

MondayJun 03, 2024 3:48 pm

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Releases Q1 2024 Quarterly Report

Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceuticals and technology, is reporting its first-quarter 2024 revenues. According to the report, the company saw revenues of $408,532 while also strengthening its balance sheet with the completion of an $8.4 million private placement involving existing and new shareholders; shares for the placement were offered at $4 per share. Nutriband also reported a cash position of $8,347,739. In the report, the company observed that it been focused on using penetration pricing to gain a foothold. “Meanwhile in Q1, the company has made further advancements in its development of AVERSA, and it is maintaining…

FridayMay 31, 2024 2:15 pm

QualityStocksNewsBreaks – Why Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’

Nutriband (NASDAQ: NTRB) is engaged in the development of a portfolio of transdermal pharmaceutical products. “The company’s AVERSA(TM) can be incorporated into any transdermal patch and includes aversive agents to prevent misuse and accidental exposure to drugs with abuse potential, specifically opioids. AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to patients who need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, Canada, Mexico, and Australia… Nutriband…

TuesdayMay 21, 2024 1:26 pm

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Schedules Live Investor Webinar, Q&A Session

Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceuticals and technology, will be spotlighted in an upcoming webinar, hosted by RedChip Companies. The event is slated for May 30, 2024, and will begin at 4:15 p.m. ET. Nutriband chair Serguei Melnik and CEO Gareth Sheridan will present during the event, which will provide key information for investors regarding current operations and upcoming milestones. To register for the event, visit https://ibn.fm/9REfQ To view the full press release, visit https://ibn.fm/mH9jC About Nutriband Inc. Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. The company’s lead product under development…

ThursdayMay 16, 2024 1:10 pm

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Names Seasoned Business Leader to Board of Directors

Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceutical solutions, has announced a new member of its board of directors. According to the announcement, Sergei Glinka, a seasoned and highly respected business executive, will serve on the board. An Estonian citizen, Glinka has served in several executive and board roles positions in large European companies, including Automecanica Skb Property Srl., GST Investments OU and TG Biochemicals Ltd. Glinka’s expertise will support and facilitate new licensing and networking opportunities for Nutriband throughout Europe as the company works to expand its AVERSA(TM) technology, which is patented in 45 countries. The announcement noted that…

MondayMay 06, 2024 9:00 am

Fentanyl Scourge: Nutriband Inc.’s (NASDAQ: NTRB) New Transdermal Patch with Abuse-Deterrent Tech Funded to Seek FDA Approval

150+ Americans die every day from synthetic opioid (e.g. fentanyl) overdose Nutriband’s AVERSA(TM) Fentanyl technology is being developed as an innovative solution to abuse and misuse rates in prescription opioid patch medications Nutriband raised $8.4 million in a private placement to fund AVERSA Fentanyl through FDA Approval Process Fentanyl addiction continues to devastate communities, with current treatment options facing limitations. However, as often happens in healthcare, innovation breeds hope with a new option on the horizon planning to seek FDA marketing approval. The challenges related to the powerful painkiller (up to 50x stronger than heroin and 100x stronger than morphine)…

TuesdayApr 23, 2024 9:45 am

Nutriband Inc. (NASDAQ: NTRB) Advances Abuse Deterrent Tech Addressing Fentanyl Epidemic

Fentanyl is a potent opioid that is associated with a significant risk of abuse and overdose, contributing to a major drug crisis in the United States Fentanyl has legitimate medical uses in managing severe and chronic pain in medical settings such as hospitals and surgical procedures NTRB is advancing its AVERSA(TM) technology that incorporates aversive agents to prevent abuse, diversion, misuse, and accidental exposure to opioids and other drugs with abuse potential NTRB was recently granted a patent for AVERSA(TM), strengthening its intellectual property portfolio in the United States and globally across 45 countries Fentanyl, a potent opioid, poses a…

FridayApr 19, 2024 11:16 am

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Enters Into Private Placement Agreements to Raise Funds for Development of AVERSA Fentanyl

Nutriband (NASDAQ: NTRB), a company engaged in the development of abuse-deterrent pharmaceutical products, has entered into definitive securities purchase agreements. The agreements are for the purchase and sale of up to 2,100,000 shares of common stock, with each share offered at $4 per share. According to the announcement, for each share of common stock purchased the investor receives a five-year warrant to purchase two shares of common stock; the exercise price for the warrants is $6.43 per share. The company anticipates using the funds from the private placement, which is expected to close on or about April 19, 2024, to…

WednesdayApr 10, 2024 9:45 am

Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’

Nutriband’s AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, like fentanyl, while keeping these drugs accessible to patients AVERSA technology can be incorporated into any transdermal patch The company has a broad intellectual property portfolio protecting AVERSA, with patents granted in the U.S., Europe, Japan, Korea, Russia, Canada, Mexico and Australia Nutriband announced in March 2024 that it will submit a New Drug Application to the FDA seeking approval to market AVERSA Fentanyl, its abuse-deterrent fentanyl transdermal patch In April 2024, the company announced it had received a contract manufacturing order from…

MondayApr 01, 2024 1:51 pm

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Begins Manufacturing for Major Sports Brand Licensee

Nutriband (NASDAQ: NTRB, NTRBW), a pharmaceutical company with a specific focus on transdermal technologies, today announced it has been engaged by and received a first order from Fit For Life Group (“FFL”), a major brand license holder. Nutriband expects a fully executed supplier agreement to follow. Under the agreement Nutriband’s wholly owned contract manufacturing subsidiary, Active Intelligence, will act as manufacturer. “This purchase order from FFL allows Nutriband and our contract manufacturing subsidiary, Active Intelligence, to once again demonstrate our capabilities in the development and manufacturing of innovative products,” said Gareth Sheridan, CEO of Nutriband. “We are excited to continue…

WednesdayDec 14, 2022 3:54 pm

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Announces Approval to Dual List, to Commence Trading on Upstream

Nutriband (NASDAQ: NTRB, NTRBW) has announced its approval to dual list its shares on Upstream, the revolutionary trading app for digital securities and NFTs powered by Horizon Fintex and MERJ Exchange Limited. The company’s trading is expected to commence on Upstream under ticker symbol NTRB at 10:00am ET on Jan. 5, 2023. “Building shareholder value and increasing our liquidity is always a high priority for us,” said Gareth Sheridan, CEO of Nutriband. “We believe a dual listing on Upstream will act as an excellent vehicle to reach an untapped international market of potential new shareholders. As we continue to develop…

Site Search

Company Search

Tag: Nutriband Inc. NTRB